NYSE:TEVAPharmaceuticals
Teva (NYSE:TEVA) Valuation Check After New Schizophrenia Drug Filing and Growing Growth Optimism
Teva Pharmaceutical Industries (TEVA) just put another stake in the ground with its FDA submission for a once monthly olanzapine injectable for schizophrenia, adding fresh momentum to a stock that has already been trending higher.
See our latest analysis for Teva Pharmaceutical Industries.
The NDA caps a string of upbeat catalysts for Teva, from a golden cross on the chart to stronger branded drug growth and fresh interest from big investors like Glenview. The stock’s 30 day share price...